Latest News

Quanta Fluid News

Quanta Appoints World Leading Nephrologist to Medical Advisory Board

3rd February 2017

Seroba’s investee company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for the clinic and the home, today announces it has appointed Dr Sandip Mitra to its Medical Advisory Board. Sandip is […]

Read More
Opsona News 2

Preliminary results in Opsona’s myelodysplastic syndrome study

20th December 2016

Dublin, Ireland – Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, today announces the preliminary results from its ongoing prospective, open label Phase I/II study […]

Read More
Labcyte News Logo

Labcyte Announces Collaboration with Notable Labs

7th December 2016

Sunnyvale, CA, and San Francisco, CA. 7 December 2016.  Labcyte Inc. and Notable Labs today announced a collaboration to apply the unique capabilities of Labcyte’s revolutionary Echo® acoustic liquid handling technology to screen individual cancer patients’ tumor cells.  This functional […]

Read More
Opsona News

Opsona presents preliminary results at 58th Annual ASH Meeting

22nd November 2016

Seroba’s investee company, Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, today announced that it will present preliminary results from its ongoing prospective, open label […]

Read More
Opsona News 3

Opsona receives orphan designation for MDS with OPN-305.

25th October 2016

Seroba’s investee company, Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug and development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, today announced that it has received orphan drug designation (ODD) from United States […]

Read More
Veryan Premarket Approval

Veryan Completes enrolment into the MIMICS-2 clinical study

24th October 2016

The MIMICS-2 study is a prospective, multicentre, interventional study designed to evaluate the safety and effectiveness of BioMimics 3D in the treatment of patients with symptomatic femoropopliteal disease. The Study is being conducted under a USA Food and Drug Administration […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top